HC Wainwright Reiterates Buy Rating for Galectin Therapeutic

HC Wainwright reissued their buy rating on shares of Galectin Therapeutics (NASDAQ:GALT – Free Report) in a report released on Tuesday morning, Benzinga reports. The firm currently has a $11.00 price target on the stock. HC Wainwright also issued estimates for Galectin Therapeutics’ Q3 2023 earnings at ($0.16) EPS, Q4 2023 earnings at ($0.16) EPS, […]

Related Keywords

, Atria Wealth Solutions Inc , Galectin Therapeutics Inc , Galectin Therapeutics Company Profile , Investors Services , Financial Services Group Inc , Centaurus Financial Inc , Galectin Therapeutics , Free Report , Services Group , Wealth Solutions , Street Corp , Get Free Report , Therapeutics Inc , Galectin Therapeutics Daily , Nasdaq Galt , Galt , Medical , Reiterated Rating , Hc Wainwright ,